Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.14740/jocmr4201 http://scihub22266oqcxt.onion/10.14740/jocmr4201 32587649!7295552!32587649     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Clin+Med+Res 2020 ; 12 (6): 329-343 Nephropedia Template TP {{tp|p=32587649|t=2020. Medical Management of COVID-19: Evidence and Experience |pdf=|usr=}}{{32587649}} gab.com Text Medical Management of COVID-19: Evidence and Experience JO: J Clin Med Res http://www.kidney.de/pget.php?&tw=1&pmid=32587649 #FOAvip Coronavirus disease 2019 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and this infectious disease is termed COVID-19 in short. On a global scale, as of June 1, 2020, the World Health Organization (WHO) published statistics of 6,057,853 infected patients and 371,166 deaths worldwide. Despite reported observational data about the experimental use of certain drugs, there is no conclusively proven curative therapy for COVID-19 as of now; however, remdesivir received emergency use authorization (EUA) by the Food and Drug Administration (FDA) recently for use in patients hospitalized with COVID-19. There are several ongoing clinical trials related to the pharmacological choices of therapy for COVID-19 patients; however, drug trials related to observational studies so far have yielded mixed results and therefore have created a sense of confusion among healthcare professionals (HCPs). In this review article, we seek to collate and provide a summary of treatment strategies for COVID-19 patients with a variable degree of illness and discuss pharmacologic and other therapies intended to be used either as experimental medicine/therapy or as part of supportive care in complicated cases of COVID-19. Twit Text FOAVip Medical Management of COVID-19: Evidence and Experience ????J Clin Med Res http://www.kidney.de/pget.php?&tw=1&pmid=32587649 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32587649 #FOAvip English Wikipedia <ref>{{Cite pmid|32587649}}</ref> Medical Management of COVID-19: Evidence and Experience #MMPMID32587649 Bose S; Adapa S; Aeddula NR; Roy S; Nandikanti D; Vupadhyayula PM; Naramala S; Gayam V; Muppidi V; Konala VM J Clin Med Res 2020[Jun]; 12 (6): 329-343 PMID32587649show ga Coronavirus disease 2019 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and this infectious disease is termed COVID-19 in short. On a global scale, as of June 1, 2020, the World Health Organization (WHO) published statistics of 6,057,853 infected patients and 371,166 deaths worldwide. Despite reported observational data about the experimental use of certain drugs, there is no conclusively proven curative therapy for COVID-19 as of now; however, remdesivir received emergency use authorization (EUA) by the Food and Drug Administration (FDA) recently for use in patients hospitalized with COVID-19. There are several ongoing clinical trials related to the pharmacological choices of therapy for COVID-19 patients; however, drug trials related to observational studies so far have yielded mixed results and therefore have created a sense of confusion among healthcare professionals (HCPs). In this review article, we seek to collate and provide a summary of treatment strategies for COVID-19 patients with a variable degree of illness and discuss pharmacologic and other therapies intended to be used either as experimental medicine/therapy or as part of supportive care in complicated cases of COVID-19. äMedical Management of COVID-19: Evidence and Experience (epmc).pdf DeepDyve Pubget Overpricing